163 related articles for article (PubMed ID: 36689171)
1. DRD2 expression based on
Tang H; Cheng Y; Lou X; Yao H; Xie J; Gu W; Huang X; Liu Y; Lin S; Dai Y; Xue L; Lin X; Wu ZB
Endocrine; 2023 May; 80(2):419-424. PubMed ID: 36689171
[TBL] [Abstract][Full Text] [Related]
2. Use of micro-positron emission tomography with (18)F-fallypride to measure the levels of dopamine receptor-D2 and (18)F-FDG as molecular imaging tracer in the pituitary glands and prolactinomas of Fischer-344 rats.
Li P; Gui S; Cao L; Gao H; Bai J; Li C; Zhang Y
Onco Targets Ther; 2016; 9():2057-68. PubMed ID: 27103832
[TBL] [Abstract][Full Text] [Related]
3. The KBTBD6/7-DRD2 axis regulates pituitary adenoma sensitivity to dopamine agonist treatment.
Liu YT; Liu F; Cao L; Xue L; Gu WT; Zheng YZ; Tang H; Wang Y; Yao H; Zhang Y; Xie WQ; Ren BH; Xiao ZH; Nie YJ; Hu R; Wu ZB
Acta Neuropathol; 2020 Sep; 140(3):377-396. PubMed ID: 32572597
[TBL] [Abstract][Full Text] [Related]
4.
Damian A; Pineyro MM; Quagliata A; Risso M; Montiglia P; Lima R; Alonso O
World J Nucl Med; 2021; 20(3):286-293. PubMed ID: 34703398
[TBL] [Abstract][Full Text] [Related]
5. The role of MAPK11/12/13/14 (p38 MAPK) protein in dopamine agonist-resistant prolactinomas.
Wang S; Wang A; Zhang Y; Zhu K; Wang X; Chen Y; Wu J
BMC Endocr Disord; 2021 Nov; 21(1):235. PubMed ID: 34814904
[TBL] [Abstract][Full Text] [Related]
6. 18F-FDOPA Uptake Reflects the Efficacy of Dopamine Agonists Treatment in Pituitary Prolactinoma.
Heimburger C; Bund C; Addeo P; Goichot B; Imperiale A
Clin Nucl Med; 2018 Sep; 43(9):e324-e325. PubMed ID: 30052596
[TBL] [Abstract][Full Text] [Related]
7. Genes differentially expressed in prolactinomas responsive and resistant to dopamine agonists.
Passos VQ; Fortes MA; Giannella-Neto D; Bronstein MD
Neuroendocrinology; 2009; 89(2):163-70. PubMed ID: 18791324
[TBL] [Abstract][Full Text] [Related]
8. Cabergoline and prolactinomas: lack of association between DRD2 polymorphisms and response to treatment.
Bueno C; Trarbach EB; Bronstein MD; Glezer A
Pituitary; 2017 Jun; 20(3):295-300. PubMed ID: 27848079
[TBL] [Abstract][Full Text] [Related]
9.
Bashari WA; van der Meulen M; MacFarlane J; Gillett D; Senanayake R; Serban L; Powlson AS; Brooke AM; Scoffings DJ; Jones J; O'Donovan DG; Tysome J; Santarius T; Donnelly N; Boros I; Aigbirhio F; Jefferies S; Cheow HK; Mendichovszky IA; Kolias AG; Mannion R; Koulouri O; Gurnell M
Pituitary; 2022 Aug; 25(4):573-586. PubMed ID: 35608811
[TBL] [Abstract][Full Text] [Related]
10. Drug resistance mechanisms in dopamine agonist-resistant prolactin pituitary neuroendocrine tumors and exploration for new drugs.
Cheng J; Xie W; Chen Y; Sun Y; Gong L; Wang H; Li C; Zhang Y
Drug Resist Updat; 2024 Mar; 73():101056. PubMed ID: 38277755
[TBL] [Abstract][Full Text] [Related]
11. Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas.
Fusco A; Gunz G; Jaquet P; Dufour H; Germanetti AL; Culler MD; Barlier A; Saveanu A
Eur J Endocrinol; 2008 May; 158(5):595-603. PubMed ID: 18426817
[TBL] [Abstract][Full Text] [Related]
12. Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.
Colao A; Ferone D; Lastoria S; Cerbone G; Di Sarno A; Di Somma C; Lucci R; Lombardi G
Clin Endocrinol (Oxf); 2000 Apr; 52(4):437-45. PubMed ID: 10762286
[TBL] [Abstract][Full Text] [Related]
13. Predictors of dopamine agonist resistance in prolactinoma patients.
Vermeulen E; D'Haens J; Stadnik T; Unuane D; Barbe K; Van Velthoven V; Gläsker S
BMC Endocr Disord; 2020 May; 20(1):68. PubMed ID: 32429916
[TBL] [Abstract][Full Text] [Related]
14. Somatostatin receptor sst2 gene transfer in human prolactinomas in vitro: impact on sensitivity to dopamine, somatostatin and dopastatin, in the control of prolactin secretion.
Cuny T; Mohamed A; Graillon T; Roche C; Defilles C; Germanetti AL; Couderc B; Figarella-Branger D; Enjalbert A; Barlier A; Saveanu A
Mol Cell Endocrinol; 2012 May; 355(1):106-13. PubMed ID: 22348806
[TBL] [Abstract][Full Text] [Related]
15. Inhibitory effects of antivascular endothelial growth factor strategies in experimental dopamine-resistant prolactinomas.
Luque GM; Perez-Millán MI; Ornstein AM; Cristina C; Becu-Villalobos D
J Pharmacol Exp Ther; 2011 Jun; 337(3):766-74. PubMed ID: 21406548
[TBL] [Abstract][Full Text] [Related]
16. Dopamine D2 receptor imaging in pituitary adenomas using iodine-123-epidepride and SPECT.
Pirker W; Riedl M; Luger A; Czech T; Rössler K; Asenbaum S; Angelberger P; Kornhuber J; Deecke L; Podreka I; Brücke T
J Nucl Med; 1996 Dec; 37(12):1931-7. PubMed ID: 8970508
[TBL] [Abstract][Full Text] [Related]
17. Resistance to dopamine agonists in prolactinoma is correlated with reduction of dopamine D2 receptor long isoform mRNA levels.
Shimazu S; Shimatsu A; Yamada S; Inoshita N; Nagamura Y; Usui T; Tsukada T
Eur J Endocrinol; 2012 Mar; 166(3):383-90. PubMed ID: 22127489
[TBL] [Abstract][Full Text] [Related]
18. T2-weighted magnetic resonance imaging characterization of prolactinomas and association with their response to dopamine agonists.
Burlacu MC; Maiter D; Duprez T; Delgrange E
Endocrine; 2019 Feb; 63(2):323-331. PubMed ID: 30267354
[TBL] [Abstract][Full Text] [Related]
19. In vivo imaging of pituitary tumours using a radiolabelled dopamine D2 receptor radioligand.
de Herder WW; Reijs AE; Kwekkeboom DJ; Hofland LJ; Nobels FR; Oei HY; Krenning EP; Lamberts SW
Clin Endocrinol (Oxf); 1996 Dec; 45(6):755-67. PubMed ID: 9039343
[TBL] [Abstract][Full Text] [Related]
20. The effect of the ANKK1/DRD2 Taq1A polymorphism on weight changes of dopaminergic treatment in prolactinomas.
Athanasoulia AP; Sievers C; Uhr M; Ising M; Stalla GK; Schneider HJ
Pituitary; 2014 Jun; 17(3):240-5. PubMed ID: 23740147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]